Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments

ACS Appl Bio Mater. 2022 Jun 20;5(6):2431-2460. doi: 10.1021/acsabm.2c00123. Epub 2022 May 18.

Abstract

The COVID-19 pandemic caused by the SARS-CoV-2, a ribonucleic acid (RNA) virus that emerged less than two years ago but has caused nearly 6.1 million deaths to date. Recently developed variants of the SARS-CoV-2 virus have been shown to be more potent and expanded at a faster rate. Until now, there is no specific and effective treatment for SARS-CoV-2 in terms of reliable and sustainable recovery. Precaution, prevention, and vaccinations are the only ways to keep the pandemic situation under control. Medical and scientific professionals are now focusing on the repurposing of previous technology and trying to develop more fruitful methodologies to detect the presence of viruses, treat the patients, precautionary items, and vaccine developments. Nanomedicine or nanobased platforms can play a crucial role in these fronts. Researchers are working on many effective approaches by nanosized particles to combat SARS-CoV-2. The role of a nanobased platform to combat SARS-CoV-2 is extremely diverse (i.e., mark to personal protective suit, rapid diagnostic tool to targeted treatment, and vaccine developments). Although there are many theoretical possibilities of a nanobased platform to combat SARS-CoV-2, until now there is an inadequate number of research targeting SARS-CoV-2 to explore such scenarios. This unique mini-review aims to compile and elaborate on the recent advances of nanobased approaches from prevention, diagnostics, treatment to vaccine developments against SARS-CoV-2, and associated challenges.

Keywords: SARS-CoV-2; antiviral therapeutics; diagnostics; nanoparticles; preventions; vaccine developments.

Publication types

  • Review

MeSH terms

  • COVID-19 Vaccines / therapeutic use
  • COVID-19* / prevention & control
  • Humans
  • Nanostructures* / therapeutic use
  • Pandemics / prevention & control
  • SARS-CoV-2 / genetics
  • Vaccine Development

Substances

  • COVID-19 Vaccines